De Boeck 1999.

Methods	RCT of those with exacerbation and those receiving elective treatment. Parallel design. Duration: 14 days. Single centre. Country: Belgium.
Participants	40 participants with CF and chronic P. aeruginosa infection (sensitive to agent under test), 46 treatments were given for treatment of an exacerbation; 29 courses for elective or suppressive treatment. Mean (SD) age 14.8 (4.4) years.
Interventions	Intervention 1: IV meropenem 150 mg/kg/day. Intervention 2: IV ceftazidime 200 mg/kg/day and tobramycin 10 mg/kg/day.
Outcomes	Lung function, weight.
Notes	We shall seek to contact the authors for IPD of those experiencing an exacerbation to reconcile the UoA issues (multiple enrolment).
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised but method not described.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Withdrawals not described.
Selective reporting (reporting bias)	Unclear risk	Narrative data in the abstract.
Other bias	High risk	UoA issues ‐ 40 participants contribute 46 treatment episodes.